Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NYSE: EW

Edwards Lifesciences Corporation

Healthcare | Medical - Devices

Market prices for EW are shown to signed-in users (sign in). This public page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$1.74

Edwards Lifesciences Corporation (NYSE: EW) is a medical device company. Figures from SEC EDGAR; updated 2026-10-20 16:05 UTC.

What Edwards Lifesciences Corporation does

Edwards Lifesciences is a structural heart company that develops medical technologies to treat advanced cardiovascular disease, with a focus on therapies for heart valve disorders and heart failure. The company offers three main product groups: transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, and surgical structural heart products. Its offerings include both catheter-based minimally invasive procedures that do not require open-heart surgery and traditional surgical approaches using bioprosthetic valves and repair devices.

Summarized from Edwards Lifesciences Corporation’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$1.74
Return on equity10.38%
Debt/equity0.06

Revenue, margins & earnings

FY2021 Net income: $1.50BFY2021 Taxes & interest: $187MFY2021 Operating expenses: $2.29BFY2021 Cost of revenue: $1.25B$5.23BFY2021FY2022 Revenue: $4.46B — margin split not shown (non-operating gains)$4.46BFY2022FY2023 Revenue: $5.01B — margin split not shown (non-operating gains)$5.01BFY2023FY2024 Revenue: $5.44B — margin split not shown (non-operating gains)$5.44BFY2024FY2025 Net income: $1.07BFY2025 Taxes & interest: $191MFY2025 Operating expenses: $3.47BFY2025 Cost of revenue: $1.33B$6.07BFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
Annual revenue; bands show net, operating, gross margins · Open in Platform →
Net income for FY2021, FY2022 is the filer’s available-to-common figure (net of preferred dividends) — the filer tags no parent net income for those years.

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-08
  • 2026-10-08CVP, TAVRSale-619$53.0K
  • 2026-10-08CVP, TAVREmployee Stock Option (Right to Acquire)Option exercise-619—
  • 2026-10-08CVP, TAVROption exercise619$45.0K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Edwards Lifesciences Corporation do?

Edwards Lifesciences is a structural heart company that develops medical technologies to treat advanced cardiovascular disease, with a focus on therapies for heart valve disorders and heart failure.

When did EW last file with the SEC?

Edwards Lifesciences Corporation's most recent SEC filing on record is a 8-K filed 2026-05-08. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 16:05 UTC. This page is also available as JSON at /api/data?ticker=EW and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for EW and 5,000+ tickers.

Create a free account — keep EW
For your agent
GET /api/data?ticker=EW

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt